OS Therapies (OSTX) said Monday it has formed OS Drug Conjugates unit and initiated a review of strategic options for its tunable antibody-drug conjugates and other tunable drug conjugates platforms.
The biotechnology company said it has started talks with antibody-drug conjugates therapeutics companies in the US, China, and other jurisdictions for potential joint ventures that will be spun off into standalone public companies.
Shares of the company rose more than 8% in recent Monday premarket activity.